REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland by the U.S. Food and Drug Administration (FDA) which started on January 10, 2024, has been concluded. Following the FDA inspection, Alvotech received a form 483 with one observation. Alvotech expects to provide the FDA with a re
Ukraine
Indonesia
India
Iceland
Philippines
Switzerland
Canada
Singapore
Japan
Israel
Reykjavik
C10